{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:08:29Z","timestamp":1790356109364,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23fk0210103s0202"],"award-info":[{"award-number":["23fk0210103s0202"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K08957"],"award-info":[{"award-number":["20K08957"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10147-026-03141-9","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:06:25Z","timestamp":1785596785000},"page":"2374-2381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical impact of salvage hepatectomy for local recurrence of hepatocellular carcinoma after radiofrequency ablation or selective transarterial chemoembolization"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4937-2062","authenticated-orcid":false,"given":"Yukako","family":"Takehara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6349-1669","authenticated-orcid":false,"given":"Yu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Morine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Teraoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Waki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Ikemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"issue":"9822","key":"3141_CR1","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379(9822):1245\u20131255. https:\/\/doi.org\/10.1016\/S0140-6736(11)61347-0","journal-title":"Lancet"},{"issue":"Suppl 4","key":"3141_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","volume":"15","author":"AP Venook","year":"2010","unstructured":"Venook AP, Papandreou C, Furuse J et al (2010) The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15(Suppl 4):5\u201313. https:\/\/doi.org\/10.1634\/theoncologist.2010-S4-05","journal-title":"Oncologist"},{"issue":"10","key":"3141_CR3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/hepr.13411","volume":"49","author":"N Kokudo","year":"2019","unstructured":"Kokudo N, Takemura N, Hasegawa K et al (2019) Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res 49(10):1109\u20131113. https:\/\/doi.org\/10.1111\/hepr.13411","journal-title":"Hepatol Res"},{"issue":"3","key":"3141_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Kawamura Y, Hasegawa K et al (2021) Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer 10(3):181\u2013223. https:\/\/doi.org\/10.1159\/000514174","journal-title":"Liver Cancer"},{"issue":"3","key":"3141_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76(3):681\u2013693. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018","journal-title":"J Hepatol"},{"issue":"4","key":"3141_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390","journal-title":"N Engl J Med"},{"issue":"1","key":"3141_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(08)70285-7","journal-title":"Lancet Oncol"},{"issue":"10126","key":"3141_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163\u20131173. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1","journal-title":"Lancet"},{"issue":"1","key":"3141_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","volume":"55","author":"T Yamashita","year":"2020","unstructured":"Yamashita T, Kudo M, Ikeda K et al (2020) REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol 55(1):113\u2013122. https:\/\/doi.org\/10.1007\/s00535-019-01642-1","journal-title":"J Gastroenterol"},{"issue":"20","key":"3141_CR10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894\u20131905","journal-title":"N Engl J Med"},{"issue":"4","key":"3141_CR11","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M et al (2022) Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 76(4):862\u2013873. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.030","journal-title":"J Hepatol"},{"issue":"13","key":"3141_CR12","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/bjs.10677","volume":"104","author":"KKC Ng","year":"2017","unstructured":"Ng KKC, Chok KSH, Chan ACY et al (2017) Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg 104(13):1775\u20131784. https:\/\/doi.org\/10.1002\/bjs.10677","journal-title":"Br J Surg"},{"issue":"3","key":"3141_CR13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1148\/radiol.2343040350","volume":"234","author":"R Lencioni","year":"2005","unstructured":"Lencioni R, Cioni D, Crocetti L et al (2005) Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 234(3):961\u2013967. https:\/\/doi.org\/10.1148\/radiol.2343040350","journal-title":"Radiology"},{"issue":"1","key":"3141_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/jgh.12441","volume":"29","author":"Y Fang","year":"2014","unstructured":"Fang Y, Chen W, Liang X et al (2014) Comparison of laparoscopic hepatectomy, percutaneous radiofrequency ablation and open hepatectomy in the treatment of small hepatocellular carcinoma. J Gastroenterol Hepatol 29(1):193\u2013200. https:\/\/doi.org\/10.1111\/jgh.12441","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"3141_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/jgh.12438","volume":"29","author":"S Siripongsakun","year":"2014","unstructured":"Siripongsakun S, Wei SH, Lin S et al (2014) Evaluation of alpha-fetoprotein in detecting hepatocellular carcinoma recurrence after radiofrequency ablation. J Gastroenterol Hepatol 29(1):157\u2013164. https:\/\/doi.org\/10.1111\/jgh.12438","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"3141_CR16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s00270-007-9003-z","volume":"30","author":"T Murakami","year":"2007","unstructured":"Murakami T, Ishimaru H, Sakamoto I et al (2007) Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence. Cardiovasc Intervent Radiol 30(4):696\u2013704. https:\/\/doi.org\/10.1007\/s00270-007-9003-z","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"3141_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000521665","volume":"11","author":"T Takayama","year":"2021","unstructured":"Takayama T, Hasegawa K, Izumi N et al (2021) Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF Trial). Liver Cancer 11(3):209\u2013218. https:\/\/doi.org\/10.1159\/000521665","journal-title":"Liver Cancer"},{"issue":"2","key":"3141_CR18","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.crad.2022.09.120","volume":"78","author":"E Hashem","year":"2023","unstructured":"Hashem E, Sait S, Thomas DN et al (2023) Transarterial chemoembolisation for very early and early stage hepatocellular carcinoma: single-centre experience. Clin Radiol 78(2):e113\u2013e122. https:\/\/doi.org\/10.1016\/j.crad.2022.09.120","journal-title":"Clin Radiol"},{"issue":"5","key":"3141_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s10147-003-0328-6","volume":"8","author":"Y Takada","year":"2003","unstructured":"Takada Y, Kurata M, Ohkohchi N (2003) Rapid and aggressive recurrence accompanied by portal tumor thrombus after radiofrequency ablation for hepatocellular carcinoma. Int J Clin Oncol 8(5):332\u2013335. https:\/\/doi.org\/10.1007\/s10147-003-0328-6","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"3141_CR20","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1245\/s10434-012-2220-y","volume":"19","author":"H Sugo","year":"2012","unstructured":"Sugo H, Ishizaki Y, Yoshimoto J et al (2012) Salvage hepatectomy for local recurrent hepatocellular carcinoma after ablation therapy. Ann Surg Oncol 19(7):2238\u20132245. https:\/\/doi.org\/10.1245\/s10434-012-2220-y","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"3141_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194745","volume":"15","author":"Y Park","year":"2023","unstructured":"Park Y, Han HS, Yoon YS et al (2023) Salvage hepatectomy for recurrent hepatocellular carcinoma after radiofrequency ablation: a retrospective cohort study with propensity score-matched analysis. Cancers (Basel) 15(19):4745. https:\/\/doi.org\/10.3390\/cancers15194745","journal-title":"Cancers (Basel)"},{"issue":"5","key":"3141_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.hpb.2020.09.010","volume":"23","author":"S Imura","year":"2021","unstructured":"Imura S, Yamada S, Saito Y et al (2021) Utility of cone unit liver resection for small hepatocellular carcinoma: a propensity score matched analysis. HPB (Oxford) 23(5):739\u2013745. https:\/\/doi.org\/10.1016\/j.hpb.2020.09.010","journal-title":"HPB (Oxford)"},{"key":"3141_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.895678","volume":"12","author":"J Yang","year":"2022","unstructured":"Yang J, Guo W, Lu M (2022) Recent perspectives on the mechanism of recurrence after ablation of hepatocellular carcinoma: a mini-review. Front Oncol 12:895678. https:\/\/doi.org\/10.3389\/fonc.2022.895678","journal-title":"Front Oncol"},{"issue":"Suppl 3","key":"3141_CR25","doi-asserted-by":"publisher","first-page":"S436","DOI":"10.1245\/s10434-014-3575-z","volume":"21","author":"S Yamada","year":"2014","unstructured":"Yamada S, Utsunomiya T, Morine Y et al (2014) Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy. Ann Surg Oncol 21(Suppl 3):S436\u2013S442","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"3141_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/hepr.12705","volume":"47","author":"T Ikemoto","year":"2017","unstructured":"Ikemoto T, Shimada M, Yamada S (2017) Pathophysiology of recurrent hepatocellular carcinoma after radiofrequency ablation. Hepatol Res 47(1):23\u201330","journal-title":"Hepatol Res"},{"issue":"5","key":"3141_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037266","volume":"7","author":"J Kong","year":"2012","unstructured":"Kong J, Pan B, Ke S et al (2012) Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1\u03b1\/VEGFA. PLoS ONE 7(5):e37266. https:\/\/doi.org\/10.1371\/journal.pone.0037266","journal-title":"PLoS ONE"},{"issue":"Suppl 3","key":"3141_CR28","doi-asserted-by":"publisher","first-page":"S436","DOI":"10.1245\/s10434-014-3575-z","volume":"21","author":"S Yamada","year":"2014","unstructured":"Yamada S, Utsunomiya T, Morine Y et al (2014) Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy. Ann Surg Oncol 21(Suppl 3):S436-442","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"3141_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2016.02.041","volume":"375","author":"S Iwahashi","year":"2016","unstructured":"Iwahashi S, Shimada M, Utsunomiya T et al (2016) Epithelial-mesenchymal transition-related genes are linked to aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation. Cancer Lett 375(1):47\u201350. https:\/\/doi.org\/10.1016\/j.canlet.2016.02.041","journal-title":"Cancer Lett"},{"issue":"1","key":"3141_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1478-3231.1999.tb00005.x","volume":"19","author":"N Kobayashi","year":"1999","unstructured":"Kobayashi N, Ishii M, Ueno Y et al (1999) Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization. Liver 19(1):25\u201331. https:\/\/doi.org\/10.1111\/j.1478-3231.1999.tb00005.x","journal-title":"Liver"},{"issue":"2","key":"3141_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1046\/j.1365-2559.2001.01064.x","volume":"38","author":"YB Kim","year":"2001","unstructured":"Kim YB, Park YN, Park C (2001) Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology 38(2):160\u2013166. https:\/\/doi.org\/10.1046\/j.1365-2559.2001.01064.x","journal-title":"Histopathology"},{"issue":"1","key":"3141_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s0168-8278(03)00503-8","volume":"40","author":"S Yasuda","year":"2004","unstructured":"Yasuda S, Arii S, Mori A et al (2004) Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. J Hepatol 40(1):117\u2013123. https:\/\/doi.org\/10.1016\/s0168-8278(03)00503-8","journal-title":"J Hepatol"},{"issue":"5","key":"3141_CR33","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.3892\/ijo.2016.3421","volume":"48","author":"M Huang","year":"2016","unstructured":"Huang M, Wang L, Chen J et al (2016) Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1\u03b1 is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery. Int J Oncol 48(5):2144\u20132154. https:\/\/doi.org\/10.3892\/ijo.2016.3421","journal-title":"Int J Oncol"},{"issue":"1","key":"3141_CR34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1148\/radiol.15141215","volume":"276","author":"TW Kang","year":"2015","unstructured":"Kang TW, Lim HK, Lee MW et al (2015) Aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation: risk factors and clinical significance. Radiology 276(1):274\u2013285. https:\/\/doi.org\/10.1148\/radiol.15141215","journal-title":"Radiology"},{"issue":"5","key":"3141_CR35","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.2214\/AJR.16.16080","volume":"207","author":"KD Song","year":"2016","unstructured":"Song KD, Lee MW, Rhim H et al (2016) Aggressive intrasegmental recurrence of hepatocellular carcinoma after combined transarterial chemoembolization and radiofrequency ablation. AJR Am J Roentgenol 207(5):1122\u20131127. https:\/\/doi.org\/10.2214\/AJR.16.16080","journal-title":"AJR Am J Roentgenol"},{"key":"3141_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2021.109955","volume":"144","author":"X Lv","year":"2021","unstructured":"Lv X, Chen M, Kong C et al (2021) Construction of a novel radiomics nomogram for the prediction of aggressive intrasegmental recurrence of HCC after radiofrequency ablation. Eur J Radiol 144:109955. https:\/\/doi.org\/10.1016\/j.ejrad.2021.109955","journal-title":"Eur J Radiol"},{"issue":"1","key":"3141_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23315-5","volume":"12","author":"E Gigante","year":"2022","unstructured":"Gigante E, Haddad Y, Nault JC et al (2022) Imaging and histological features of tumor biopsy sample predict aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation. Sci Rep 12(1):18712. https:\/\/doi.org\/10.1038\/s41598-022-23315-5","journal-title":"Sci Rep"},{"issue":"3","key":"3141_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.surg.2014.10.019","volume":"157","author":"S Yamashita","year":"2015","unstructured":"Yamashita S, Aoki T, Inoue Y et al (2015) Outcome of salvage hepatic resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy. Surgery 157(3):463\u2013472. https:\/\/doi.org\/10.1016\/j.surg.2014.10.019","journal-title":"Surgery"},{"issue":"1","key":"3141_CR39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000511157","volume":"38","author":"Y Wang","year":"2021","unstructured":"Wang Y, Liao Y, Liu W et al (2021) Surgical resection versus re-ablation for intrahepatic recurrent hepatocellular carcinoma after initial ablation therapy. Dig Surg 38(1):46\u201357. https:\/\/doi.org\/10.1159\/000511157","journal-title":"Dig Surg"},{"issue":"5","key":"3141_CR40","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1007\/s00268-015-2956-1","volume":"39","author":"SC Thomasset","year":"2015","unstructured":"Thomasset SC, Dennison AR, Garcea G (2015) Ablation for recurrent hepatocellular carcinoma: a systematic review of clinical efficacy and prognostic factors. World J Surg 39(5):1150\u20131160. https:\/\/doi.org\/10.1007\/s00268-015-2956-1","journal-title":"World J Surg"},{"issue":"1","key":"3141_CR41","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1080\/02656736.2021.2024279","volume":"39","author":"Y Tan","year":"2022","unstructured":"Tan Y, Wang X, Ma K et al (2022) Risk factors for the recurrence of early hepatocellular carcinoma treated by percutaneous radiofrequency ablation with a multiple-electrode switching system: a multicenter prospective study. Int J Hyperthermia 39(1):190\u2013199. https:\/\/doi.org\/10.1080\/02656736.2021.2024279","journal-title":"Int J Hyperthermia"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03141-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03141-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03141-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:49:48Z","timestamp":1790354988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03141-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3141"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03141-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7596800\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Tokushima University Hospital Ethics Committee, and the experiments were performed in accordance with the approval guidelines (Tokushima Clinical Trial Management System Number, 3215-3), and was carried out in compliance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients involved in the study signed the informed consent form and agreed to participate.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}